SCHEMBL17015945

SCHEMBL17015945

c1ccc(-c2cc3ccc4c5ccccc5n(-c5cccc(-n6c7ccccc7c7ccccc76)c5)c4c3n2-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ATM Q13315 1/20 0.47
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 4/20 0.35
▸ IL1R1 P14778 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ GAA P10253 1/20 0.34
▸ HAO1 Q9UJM8 1/20 0.34
▸ APP P05067 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ BCHE P06276 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ MAPK8 P45983 1/20 0.32
▸ MAPK9 P45984 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015942 0.95 L3MBTL1 (0.50) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015950 0.94 L3MBTL1 (0.42) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015947 0.93 L3MBTL1 (0.41) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015944 0.93 L3MBTL1 (0.41) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015943 0.92 L3MBTL1 (0.45) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015883 0.91 L3MBTL1 (0.42) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL15632271 0.91 L3MBTL1 (0.45) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015938 0.91 L3MBTL1 (0.38) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015886 0.90 L3MBTL1 (0.40) KDM4EL3MBTL1ATMTSHRKMT2A
SCHEMBL17015902 0.90 L3MBTL1 (0.40) KDM4EL3MBTL1ATMTSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885L3MBTL1 533/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback